Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norepinephrine vs dobutamine in cardiogenic shock
2024-520399-84-00Phase 4Authorised
- Sponsor
- Azienda USL Toscana Sud Est
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cardiogenic shock comparing Norepinephrine arm with Dobutamine arm (2 arms). Primary endpoint: Change in blood lactate concentration at 72 hours. Planned start Feb 2025; status: authorised.
02
Drugs
norepinephrinedobutamine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2024-520399-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520399-84-00.